Table 4 Influence of different combined oral contraceptive formulations in the hyperandrogenemic biomarkers of polycystic ovary syndrome
COC formulation | Number of studies | Before Md (1st – 3rd) | After Md (1st – 3rd) | ∆ | p* |
|---|---|---|---|---|---|
SHBG (nmol/l) | |||||
 EE 35 μg / CPA 2 mg | 12 | 37.3 (32.7–52.9) | 179.0 (122.1–235.7) | +141.7 | 0.002 |
 EE 30 μg / DRSP 3 mg | 15 | 35.8 (29.9–45.3) | 140.8 (62.8–180.0) | +105.0 | <0.001 |
 EE 30 μg / CMA 2 mg | 06 | 38.8 (27.0–42.9) | 181.9 (140.0–217.9) | +143.1 | 0.027 |
 EE 30 μg / DSG 75–150 μg | 05 | 30.0 (22.5–30.0) | 76.0 (60–129) | +46.0 | 0.043 |
 EE 30 μg / GSD 75 μg | 02 | 21.7 (17.5–26.0) | 109.2 (87–131.0) | +65.4 | 0.049 |
Total T (ng/dl) | |||||
 EE 35 μg / CPA 2 mg | 11 | 79.5 (31.2–100.0) | 46.9 (30.0–66.1) | −32.5 | 0.003 |
 EE 30 μg / DRSP 3 mg | 15 | 66.5 (60.0–86.4) | 48.9 (39.0–55.0) | −17.6 | <0.001 |
 EE 30 μg / CMA 2 mg | 05 | 78.0 (73.4–84.1) | 41.9 (45.8–60.3) | −36.1 | 0.043 |
 EE 30 μg / DSG 75–150 μg | 07 | 52.3 (44.0–67.4) | 36.1 (31.0–42.0) | −16.2 | 0.027 |
 EE 30 μg / GSD 75 μg | 02 | 72.7 (64.4–81.0) | 51.8 (47.5–56.0) | 19.9 | 0.179 |
Free T (pmol/l) | |||||
 EE 35 μg / CPA 2 mg | 07 | 4.3 (2.8–8.8) | 2.4 (1.5–5.9) | −1.9 | 0.011 |
 EE 30 μg / DRSP 3 mg | 05 | 2.2 (2.2–2.4) | 1.9 (1.1–1.96) | −0.3 | 0.043 |
 EE 30 μg / CMA 2 mg | 05 | 7.8 (6.1–7.9) | 4.2 (3.8–4.7) | −3.6 | 0.043 |
 EE 30 μg / DSG 150 μg | 04 | 2.6 (1.6–6.8) | 1.4 (1.0–1.7) | −1.2 | 0.067 |
FAI (%) | |||||
 EE 35 μg / CPA 2 mg | 07 | 10.2 (5.4–11.5) | 2.1 (0.8–2.8) | −8.0 | 0.042 |
 EE 30 μg / DRSP 3 mg | 14 | 6.8 (5.1–9.3) | 1.2 (0.9–4.2) | −5.6 | 0.001 |
 EE 30 μg / CMA 2 mg | 05 | 9.4 (7.9–9.7) | 0.9 (0.9–0.94) | −8.5 | 0.043 |
 EE 30 μg / DSG 75–150 μg | 05 | 4.8 (3.0–6.4) | 0.7 (0.6–0.74) | −4.1 | 0.043 |